News & Events

Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine

SEATTLE, September 3, 2019 — Impel NeuroPharma today announced the last patient has been enrolled in “STOP-301” (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute…


Impel NeuroPharma to Present Data from INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

SEATTLE, July 10, 2019 — Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DHE) Delivered by Impel’s POD® Device, Support Bioavailability, Safety and Tolerability Profile of INP104 for Acute Migraine. Company’s Phase 3 Clinical…


Impel NeuroPharma Appoints John Leaman as Chief Financial Officer

SEATTLE, June 26, 2019 — Impel NeuroPharma today announced the appointment of John Leaman, M.D., as the Company’s Chief Financial Officer.